William Blair analyst Andy Hsieh maintained a Hold rating on Lantheus (LNTH – Research Report) today. The company’s shares closed today at ...

Lantheus Holdings (NasdaqGM:LNTH) saw an 18.83% increase in its share price over the past week, driven by recent corporate updates and market trends. The company announced its 2024 earnings, reporting ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Certara (CERT – Research Report), Lantheus ...

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) reported 2024 financial and operational results on February 26 th , producing sales of over $1 billion for Pylarify during ...

Prostate imaging drug Pylarify has become the first radiodiagnostic blockbuster, achieving over $1 billion in sales for 2024. The addressable market continues to expand.

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

Lantheus Holdings shares rose after its adjusted earnings for the fourth quarter and 2025 outlook estimates were higher than expected. The stock climbed 20%, to $96.36. The stock has gained about half ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) reported Q4 CY2024 results , with sales up 10.5% year on year to ...

Lantheus Holdings expects full-year earnings in the range of $7 to $7.20 per share, with revenue in the range of $1.55 billion to $1.61 billion. This story was generated by Automated Insights ( http:/ ...

Principal Financial Group Inc. reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Free Report) by 22.7% during the 4th quarter, according to the company in its most recent 13F ...

Explore the exciting world of Lantheus Holdings (NASDAQ: LNTH) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight ...